《2019年欧洲心脏病学会和欧洲糖尿病研究学会糖尿病管理指南》解读
胡蒙亮,刘梅林
摘要(Abstract)：
<正>由于生活方式的改变,糖尿病(diabetes mellitus,DM)患病率持续增加,中国和印度等国家的患病率高达10%[1]。至2017年,欧洲约有6000万人患有2型糖尿病(type 2 diabetes mellitus,T2DM),其中有半数未被诊断,对其心血管造成了严重影响[2]。预测到2045年,全球将有超过6亿人发展为T2DM。2019年8月31日欧洲心脏病学会(European Society of Cardiology,ESC)及欧洲糖尿病研究学会(European Association for the Study of Diabetes,EASD)等多个学术团体联合颁布了《2019年ESC/EASD糖尿病管理指南》(以下简称
关键词(KeyWords)： 心血管疾病;糖尿病;指南解读
基金项目(Foundation):
作者(Author): 胡蒙亮,刘梅林
参考文献(References)：
- [1] Gwatidzo SD,Stewart Williams J. Diabetes mellitus medication use and catastrophic healthcare expenditure among adults aged 50+years in China and India:results from the WHO study on global AGEing and adult health(SAGE). BMC Geriatr, 2017, 17(1):14.
- [2] Cho NH, Shaw JE, Karuranga S, et al. IDF diabetes atlas:Global estimates of diabetes prevalence for 2017 and projections for 2045.Diabetes Res Clin Pract, 2018, 138:271-281.
- [3] Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J, 2019.[Epub ahead of print]
- [4] Rydén L, Grant PJ, Anker SD, et al. ESC Guidelines on diabetes,pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD:the task force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology(ESC)and developed in collaboration with the European Association for the Study of Diabetes(EASD). Eur Heart J, 2013,34(39):3035-3087.
- [5] American Diabetes Association. 4. Lifestyle management:standards of medical care in diabetes-2018. Diabetes Care, 2018, 41(Suppl 1):S38-S50.
- [6] Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. The task force on myocardial revascularization of the European Society of Cardiology(ESC)and European Association for Cardio-Thoracic Surgery(EACTS)]. G Ital Cardiol(Rome), 2019, 20(7):1-61.
- [7] Oellgaard J, Gaede P, Rossing P, et al. Reduced risk of heart failure with intensified multifactorial intervention in individuals with type 2 diabetes and microalbuminuria:21 years of follow-up in the randomised Steno-2 study. Diabetologia, 2018, 61(8):1724-1733.
- [8] Bain S, Druyts E, Balijepalli C, et al. Cardiovascular events and allcause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs:A Bayesian meta-analysis of survival data. Diabetes Obes Metab, 2017, 19(3):329-335.
- [9] Lenzen M, Ryden L, Ohrvik J, et al. Diabetes known or newly detected, but not impaired glucose regulation, has a negative influence on 1-year outcome in patients with coronary artery disease:a report from the Euro Heart Survey on diabetes and the heart. Eur Heart J, 2006, 27(24):2969-2974.
- [10] Aronow WS, Ahn C, Kronzon I. Comparison of incidences of congestive heart failure in older African-Americans, Hispanics, and whites. Am J Cardiol, 1999, 84(5):611-612,A9.
- [11] Johansson I, Dahlstrom U, Edner M, et al. Type 2 diabetes and heart failure:Characteristics and prognosis in preserved, mid-range and reduced ventricular function. Diab Vasc Dis Res, 2018, 15(6):494-503.
- [12] Eriksson JW, Bodegard J, Nathanson D, et al. Sulphonylurea compared to DPP-4 inhibitors in combination with metformin carries increased risk of severe hypoglycemia, cardiovascular events, and all-cause mortality. Diabetes Res Clin Pract, 2016, 117:39-47.
- [13] Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes(UKPDS 33). UK Prospective Diabetes Study(UKPDS)Group. Lancet, 1998. 352(9131):837-853.
- [14] Holman RR, Haffner SM, McMurray JJ, et al. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med, 2010, 362(16):1463-1476.
- [15] Viberti G, Kahn SE, Greene DA, et al. A diabetes outcome progression trial(ADOPT):an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care, 2002, 25(10):1737-1743.
- [16] Pallisgaard JL, Schjerning AM, Lindhardt TB, et al. Risk of atrial fibrillation in diabetes mellitus:A nationwide cohort study. Eur J Prev Cardiol, 2016, 23(6):621-627.